A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Who May Qualify: - 18 to 70 years old at the time of signing the willing to sign a consent form Form (ICF). - Diagnosed as SLE/Immune-Mediated Necrotizing Myopathy (IMNM)/Neuromyelitis Optica Spectrum Disorders (NMOSD)/Multiple Sclerosis (MS)/Myasthenia Gravis (MG)/Systemic Sclerosis (SSc) according to recognized diagnostic criteria for at least 6 months. - Remains disease active or relapses after treatment with standard of care therapy for at least 8 weeks with the dose stable for more than 2 weeks; patients should have been treated with at least two immunosuppressants (including immunosuppressants, biologics, and disease-modifying drug (DMD) ). - Adequate bone marrow, coagulation, cardiopulmonary, liver and renal function. Who Should NOT Join This Trial: - Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human weakened immune system Virus (HIV), Treponema Pallidum (TP) positive, Cytomegalovirus (CMV) DNA positive, Epstein-Barr Virus (EBV) DNA positive. - Uncontrolled active infection. - Live vaccine injection within 4 weeks prior to signing the ICF. - Major organ transplantation history or bone marrow/hematopoietic stem cell transplantation history. - Severe cardiovascular diseases within the past 6 months prior to screening. - ≥ Grade 2 bleeding within the past 30 days prior to screening, or requiring long-term anticoagulants treatment. - Inadequate washing time for previous treatment. - Previously treated with CAR-T cell products or genetically modified T cell therapies. - Pregnant or lactating women. - Severe central nervous system diseases or pathological changes. - Malignancy history within 5 years prior to signing the ICF. Always talk to your doctor about whether this trial is right for you.